nodes	percent_of_prediction	percent_of_DWPC	metapath
Mesalazine—PPARG—thyroid cancer	0.475	0.703	CbGaD
Mesalazine—PTGS2—thyroid cancer	0.2	0.297	CbGaD
Mesalazine—CHUK—thyroid gland—thyroid cancer	0.00149	0.103	CbGeAlD
Mesalazine—PPARG—neck—thyroid cancer	0.00133	0.0912	CbGeAlD
Mesalazine—CHUK—head—thyroid cancer	0.00132	0.091	CbGeAlD
Mesalazine—Olsalazine—PPARG—thyroid cancer	0.00126	0.328	CrCbGaD
Mesalazine—IKBKB—thyroid gland—thyroid cancer	0.00102	0.0697	CbGeAlD
Mesalazine—CHUK—lymph node—thyroid cancer	0.000928	0.0637	CbGeAlD
Mesalazine—IKBKB—head—thyroid cancer	0.000901	0.0619	CbGeAlD
Mesalazine—ALOX5—thyroid gland—thyroid cancer	0.000841	0.0578	CbGeAlD
Mesalazine—Salicylate-sodium—PTGS2—thyroid cancer	0.000779	0.202	CrCbGaD
Mesalazine—ALOX5—head—thyroid cancer	0.000746	0.0513	CbGeAlD
Mesalazine—PPARG—thyroid gland—thyroid cancer	0.000632	0.0434	CbGeAlD
Mesalazine—MPO—head—thyroid cancer	0.000632	0.0434	CbGeAlD
Mesalazine—IKBKB—lymph node—thyroid cancer	0.000631	0.0433	CbGeAlD
Mesalazine—PPARG—head—thyroid cancer	0.00056	0.0385	CbGeAlD
Mesalazine—Olsalazine—PTGS2—thyroid cancer	0.000534	0.138	CrCbGaD
Mesalazine—ALOX5—lymph node—thyroid cancer	0.000523	0.0359	CbGeAlD
Mesalazine—Aminosalicylic Acid—PTGS2—thyroid cancer	0.000502	0.13	CrCbGaD
Mesalazine—Diflunisal—PTGS2—thyroid cancer	0.000502	0.13	CrCbGaD
Mesalazine—MPO—lymph node—thyroid cancer	0.000442	0.0304	CbGeAlD
Mesalazine—PTGS1—trachea—thyroid cancer	0.000427	0.0293	CbGeAlD
Mesalazine—PTGS2—trachea—thyroid cancer	0.000408	0.028	CbGeAlD
Mesalazine—PPARG—lymph node—thyroid cancer	0.000392	0.027	CbGeAlD
Mesalazine—PTGS1—thyroid gland—thyroid cancer	0.000338	0.0232	CbGeAlD
Mesalazine—PTGS1—head—thyroid cancer	0.0003	0.0206	CbGeAlD
Mesalazine—PTGS2—head—thyroid cancer	0.000286	0.0197	CbGeAlD
Mesalazine—Salicylic acid—PTGS2—thyroid cancer	0.000279	0.0723	CrCbGaD
Mesalazine—PTGS1—lymph node—thyroid cancer	0.00021	0.0144	CbGeAlD
Mesalazine—PTGS2—lymph node—thyroid cancer	0.000201	0.0138	CbGeAlD
Mesalazine—Aspartate aminotransferase increased—Epirubicin—thyroid cancer	0.000127	0.000666	CcSEcCtD
Mesalazine—Nasopharyngitis—Epirubicin—thyroid cancer	0.000126	0.000662	CcSEcCtD
Mesalazine—Face oedema—Doxorubicin—thyroid cancer	0.000126	0.000661	CcSEcCtD
Mesalazine—Gastritis—Epirubicin—thyroid cancer	0.000125	0.000655	CcSEcCtD
Mesalazine—Alanine aminotransferase increased—Epirubicin—thyroid cancer	0.000125	0.000652	CcSEcCtD
Mesalazine—Dizziness—Sorafenib—thyroid cancer	0.000124	0.000651	CcSEcCtD
Mesalazine—Mood swings—Doxorubicin—thyroid cancer	0.000124	0.000648	CcSEcCtD
Mesalazine—Abdominal distension—Epirubicin—thyroid cancer	0.000123	0.000644	CcSEcCtD
Mesalazine—Blood creatinine increased—Doxorubicin—thyroid cancer	0.000123	0.000641	CcSEcCtD
Mesalazine—Asthma—Epirubicin—thyroid cancer	0.000122	0.000639	CcSEcCtD
Mesalazine—Dysphagia—Epirubicin—thyroid cancer	0.000122	0.000639	CcSEcCtD
Mesalazine—Influenza—Epirubicin—thyroid cancer	0.000122	0.000639	CcSEcCtD
Mesalazine—Eosinophilia—Epirubicin—thyroid cancer	0.000121	0.000633	CcSEcCtD
Mesalazine—Liver function test abnormal—Doxorubicin—thyroid cancer	0.000121	0.000632	CcSEcCtD
Mesalazine—Dry skin—Doxorubicin—thyroid cancer	0.00012	0.000627	CcSEcCtD
Mesalazine—Pancreatitis—Epirubicin—thyroid cancer	0.00012	0.000627	CcSEcCtD
Mesalazine—Vomiting—Sorafenib—thyroid cancer	0.00012	0.000626	CcSEcCtD
Mesalazine—Abdominal pain upper—Doxorubicin—thyroid cancer	0.00012	0.000625	CcSEcCtD
Mesalazine—Orthostatic hypotension—Doxorubicin—thyroid cancer	0.00012	0.000625	CcSEcCtD
Mesalazine—Angina pectoris—Epirubicin—thyroid cancer	0.000119	0.000623	CcSEcCtD
Mesalazine—Rash—Sorafenib—thyroid cancer	0.000119	0.00062	CcSEcCtD
Mesalazine—Dermatitis—Sorafenib—thyroid cancer	0.000118	0.00062	CcSEcCtD
Mesalazine—Breast disorder—Doxorubicin—thyroid cancer	0.000118	0.000619	CcSEcCtD
Mesalazine—Aspartate aminotransferase increased—Doxorubicin—thyroid cancer	0.000118	0.000616	CcSEcCtD
Mesalazine—Headache—Sorafenib—thyroid cancer	0.000118	0.000616	CcSEcCtD
Mesalazine—Bronchitis—Epirubicin—thyroid cancer	0.000118	0.000615	CcSEcCtD
Mesalazine—Nasopharyngitis—Doxorubicin—thyroid cancer	0.000117	0.000612	CcSEcCtD
Mesalazine—Pancytopenia—Epirubicin—thyroid cancer	0.000116	0.000607	CcSEcCtD
Mesalazine—Gastritis—Doxorubicin—thyroid cancer	0.000116	0.000606	CcSEcCtD
Mesalazine—Alanine aminotransferase increased—Doxorubicin—thyroid cancer	0.000115	0.000604	CcSEcCtD
Mesalazine—Dysuria—Epirubicin—thyroid cancer	0.000114	0.000598	CcSEcCtD
Mesalazine—Neutropenia—Epirubicin—thyroid cancer	0.000114	0.000598	CcSEcCtD
Mesalazine—Abdominal distension—Doxorubicin—thyroid cancer	0.000114	0.000596	CcSEcCtD
Mesalazine—Upper respiratory tract infection—Epirubicin—thyroid cancer	0.000114	0.000594	CcSEcCtD
Mesalazine—Dysphagia—Doxorubicin—thyroid cancer	0.000113	0.000592	CcSEcCtD
Mesalazine—Influenza—Doxorubicin—thyroid cancer	0.000113	0.000592	CcSEcCtD
Mesalazine—Asthma—Doxorubicin—thyroid cancer	0.000113	0.000592	CcSEcCtD
Mesalazine—Pollakiuria—Epirubicin—thyroid cancer	0.000113	0.000591	CcSEcCtD
Mesalazine—Eosinophilia—Doxorubicin—thyroid cancer	0.000112	0.000586	CcSEcCtD
Mesalazine—Nausea—Sorafenib—thyroid cancer	0.000112	0.000584	CcSEcCtD
Mesalazine—Photosensitivity reaction—Epirubicin—thyroid cancer	0.000112	0.000584	CcSEcCtD
Mesalazine—Weight increased—Epirubicin—thyroid cancer	0.000111	0.000582	CcSEcCtD
Mesalazine—Pancreatitis—Doxorubicin—thyroid cancer	0.000111	0.00058	CcSEcCtD
Mesalazine—Weight decreased—Epirubicin—thyroid cancer	0.000111	0.000578	CcSEcCtD
Mesalazine—Angina pectoris—Doxorubicin—thyroid cancer	0.00011	0.000576	CcSEcCtD
Mesalazine—Pneumonia—Epirubicin—thyroid cancer	0.00011	0.000573	CcSEcCtD
Mesalazine—Infestation NOS—Epirubicin—thyroid cancer	0.000109	0.00057	CcSEcCtD
Mesalazine—Infestation—Epirubicin—thyroid cancer	0.000109	0.00057	CcSEcCtD
Mesalazine—Bronchitis—Doxorubicin—thyroid cancer	0.000109	0.000569	CcSEcCtD
Mesalazine—Stevens-Johnson syndrome—Epirubicin—thyroid cancer	0.000108	0.000565	CcSEcCtD
Mesalazine—Pancytopenia—Doxorubicin—thyroid cancer	0.000107	0.000562	CcSEcCtD
Mesalazine—Renal failure—Epirubicin—thyroid cancer	0.000107	0.00056	CcSEcCtD
Mesalazine—Neuropathy peripheral—Epirubicin—thyroid cancer	0.000107	0.000559	CcSEcCtD
Mesalazine—Jaundice—Epirubicin—thyroid cancer	0.000106	0.000556	CcSEcCtD
Mesalazine—Stomatitis—Epirubicin—thyroid cancer	0.000106	0.000556	CcSEcCtD
Mesalazine—Urinary tract infection—Epirubicin—thyroid cancer	0.000106	0.000554	CcSEcCtD
Mesalazine—Conjunctivitis—Epirubicin—thyroid cancer	0.000106	0.000554	CcSEcCtD
Mesalazine—Dysuria—Doxorubicin—thyroid cancer	0.000106	0.000553	CcSEcCtD
Mesalazine—Neutropenia—Doxorubicin—thyroid cancer	0.000106	0.000553	CcSEcCtD
Mesalazine—Upper respiratory tract infection—Doxorubicin—thyroid cancer	0.000105	0.00055	CcSEcCtD
Mesalazine—Sweating—Epirubicin—thyroid cancer	0.000104	0.000547	CcSEcCtD
Mesalazine—Pollakiuria—Doxorubicin—thyroid cancer	0.000104	0.000547	CcSEcCtD
Mesalazine—Haematuria—Epirubicin—thyroid cancer	0.000104	0.000544	CcSEcCtD
Mesalazine—Photosensitivity reaction—Doxorubicin—thyroid cancer	0.000103	0.00054	CcSEcCtD
Mesalazine—Hepatobiliary disease—Epirubicin—thyroid cancer	0.000103	0.000539	CcSEcCtD
Mesalazine—Weight increased—Doxorubicin—thyroid cancer	0.000103	0.000538	CcSEcCtD
Mesalazine—Epistaxis—Epirubicin—thyroid cancer	0.000103	0.000538	CcSEcCtD
Mesalazine—Weight decreased—Doxorubicin—thyroid cancer	0.000102	0.000535	CcSEcCtD
Mesalazine—Sinusitis—Epirubicin—thyroid cancer	0.000102	0.000535	CcSEcCtD
Mesalazine—Agranulocytosis—Epirubicin—thyroid cancer	0.000102	0.000532	CcSEcCtD
Mesalazine—Pneumonia—Doxorubicin—thyroid cancer	0.000101	0.000531	CcSEcCtD
Mesalazine—Infestation NOS—Doxorubicin—thyroid cancer	0.000101	0.000527	CcSEcCtD
Mesalazine—Infestation—Doxorubicin—thyroid cancer	0.000101	0.000527	CcSEcCtD
Mesalazine—Stevens-Johnson syndrome—Doxorubicin—thyroid cancer	0.0001	0.000523	CcSEcCtD
Mesalazine—Renal failure—Doxorubicin—thyroid cancer	9.91e-05	0.000519	CcSEcCtD
Mesalazine—Neuropathy peripheral—Doxorubicin—thyroid cancer	9.88e-05	0.000517	CcSEcCtD
Mesalazine—Haemoglobin—Epirubicin—thyroid cancer	9.83e-05	0.000514	CcSEcCtD
Mesalazine—Stomatitis—Doxorubicin—thyroid cancer	9.83e-05	0.000514	CcSEcCtD
Mesalazine—Jaundice—Doxorubicin—thyroid cancer	9.83e-05	0.000514	CcSEcCtD
Mesalazine—Rhinitis—Epirubicin—thyroid cancer	9.81e-05	0.000513	CcSEcCtD
Mesalazine—Urinary tract infection—Doxorubicin—thyroid cancer	9.8e-05	0.000513	CcSEcCtD
Mesalazine—Conjunctivitis—Doxorubicin—thyroid cancer	9.8e-05	0.000513	CcSEcCtD
Mesalazine—Hepatitis—Epirubicin—thyroid cancer	9.78e-05	0.000512	CcSEcCtD
Mesalazine—Haemorrhage—Epirubicin—thyroid cancer	9.78e-05	0.000512	CcSEcCtD
Mesalazine—Pharyngitis—Epirubicin—thyroid cancer	9.71e-05	0.000508	CcSEcCtD
Mesalazine—Sweating—Doxorubicin—thyroid cancer	9.67e-05	0.000506	CcSEcCtD
Mesalazine—Urinary tract disorder—Epirubicin—thyroid cancer	9.66e-05	0.000505	CcSEcCtD
Mesalazine—Oedema peripheral—Epirubicin—thyroid cancer	9.64e-05	0.000504	CcSEcCtD
Mesalazine—Haematuria—Doxorubicin—thyroid cancer	9.61e-05	0.000503	CcSEcCtD
Mesalazine—Connective tissue disorder—Epirubicin—thyroid cancer	9.61e-05	0.000503	CcSEcCtD
Mesalazine—Urethral disorder—Epirubicin—thyroid cancer	9.59e-05	0.000502	CcSEcCtD
Mesalazine—Hepatobiliary disease—Doxorubicin—thyroid cancer	9.54e-05	0.000499	CcSEcCtD
Mesalazine—Epistaxis—Doxorubicin—thyroid cancer	9.51e-05	0.000498	CcSEcCtD
Mesalazine—Sinusitis—Doxorubicin—thyroid cancer	9.46e-05	0.000495	CcSEcCtD
Mesalazine—Agranulocytosis—Doxorubicin—thyroid cancer	9.41e-05	0.000492	CcSEcCtD
Mesalazine—Erythema multiforme—Epirubicin—thyroid cancer	9.25e-05	0.000484	CcSEcCtD
Mesalazine—Eye disorder—Epirubicin—thyroid cancer	9.14e-05	0.000478	CcSEcCtD
Mesalazine—Tinnitus—Epirubicin—thyroid cancer	9.12e-05	0.000477	CcSEcCtD
Mesalazine—Haemoglobin—Doxorubicin—thyroid cancer	9.1e-05	0.000476	CcSEcCtD
Mesalazine—Cardiac disorder—Epirubicin—thyroid cancer	9.08e-05	0.000475	CcSEcCtD
Mesalazine—Rhinitis—Doxorubicin—thyroid cancer	9.07e-05	0.000475	CcSEcCtD
Mesalazine—Hepatitis—Doxorubicin—thyroid cancer	9.05e-05	0.000474	CcSEcCtD
Mesalazine—Haemorrhage—Doxorubicin—thyroid cancer	9.05e-05	0.000474	CcSEcCtD
Mesalazine—Pharyngitis—Doxorubicin—thyroid cancer	8.98e-05	0.00047	CcSEcCtD
Mesalazine—Urinary tract disorder—Doxorubicin—thyroid cancer	8.94e-05	0.000468	CcSEcCtD
Mesalazine—Oedema peripheral—Doxorubicin—thyroid cancer	8.92e-05	0.000466	CcSEcCtD
Mesalazine—Connective tissue disorder—Doxorubicin—thyroid cancer	8.9e-05	0.000465	CcSEcCtD
Mesalazine—Angiopathy—Epirubicin—thyroid cancer	8.88e-05	0.000464	CcSEcCtD
Mesalazine—Urethral disorder—Doxorubicin—thyroid cancer	8.87e-05	0.000464	CcSEcCtD
Mesalazine—Immune system disorder—Epirubicin—thyroid cancer	8.84e-05	0.000462	CcSEcCtD
Mesalazine—Mediastinal disorder—Epirubicin—thyroid cancer	8.82e-05	0.000461	CcSEcCtD
Mesalazine—Chills—Epirubicin—thyroid cancer	8.78e-05	0.000459	CcSEcCtD
Mesalazine—Alopecia—Epirubicin—thyroid cancer	8.64e-05	0.000452	CcSEcCtD
Mesalazine—Mental disorder—Epirubicin—thyroid cancer	8.57e-05	0.000448	CcSEcCtD
Mesalazine—Erythema multiforme—Doxorubicin—thyroid cancer	8.56e-05	0.000448	CcSEcCtD
Mesalazine—Erythema—Epirubicin—thyroid cancer	8.52e-05	0.000446	CcSEcCtD
Mesalazine—Eye disorder—Doxorubicin—thyroid cancer	8.46e-05	0.000443	CcSEcCtD
Mesalazine—Tinnitus—Doxorubicin—thyroid cancer	8.44e-05	0.000442	CcSEcCtD
Mesalazine—Cardiac disorder—Doxorubicin—thyroid cancer	8.4e-05	0.000439	CcSEcCtD
Mesalazine—Flatulence—Epirubicin—thyroid cancer	8.39e-05	0.000439	CcSEcCtD
Mesalazine—Tension—Epirubicin—thyroid cancer	8.36e-05	0.000437	CcSEcCtD
Mesalazine—Dysgeusia—Epirubicin—thyroid cancer	8.34e-05	0.000436	CcSEcCtD
Mesalazine—Nervousness—Epirubicin—thyroid cancer	8.27e-05	0.000433	CcSEcCtD
Mesalazine—Back pain—Epirubicin—thyroid cancer	8.24e-05	0.000431	CcSEcCtD
Mesalazine—Angiopathy—Doxorubicin—thyroid cancer	8.21e-05	0.00043	CcSEcCtD
Mesalazine—Muscle spasms—Epirubicin—thyroid cancer	8.19e-05	0.000428	CcSEcCtD
Mesalazine—Immune system disorder—Doxorubicin—thyroid cancer	8.18e-05	0.000428	CcSEcCtD
Mesalazine—Mediastinal disorder—Doxorubicin—thyroid cancer	8.16e-05	0.000427	CcSEcCtD
Mesalazine—Chills—Doxorubicin—thyroid cancer	8.12e-05	0.000425	CcSEcCtD
Mesalazine—Vision blurred—Epirubicin—thyroid cancer	8.03e-05	0.00042	CcSEcCtD
Mesalazine—Alopecia—Doxorubicin—thyroid cancer	8e-05	0.000418	CcSEcCtD
Mesalazine—Mental disorder—Doxorubicin—thyroid cancer	7.93e-05	0.000415	CcSEcCtD
Mesalazine—Ill-defined disorder—Epirubicin—thyroid cancer	7.9e-05	0.000413	CcSEcCtD
Mesalazine—Erythema—Doxorubicin—thyroid cancer	7.88e-05	0.000412	CcSEcCtD
Mesalazine—Anaemia—Epirubicin—thyroid cancer	7.87e-05	0.000412	CcSEcCtD
Mesalazine—Flatulence—Doxorubicin—thyroid cancer	7.76e-05	0.000406	CcSEcCtD
Mesalazine—Tension—Doxorubicin—thyroid cancer	7.73e-05	0.000405	CcSEcCtD
Mesalazine—Dysgeusia—Doxorubicin—thyroid cancer	7.72e-05	0.000404	CcSEcCtD
Mesalazine—Malaise—Epirubicin—thyroid cancer	7.68e-05	0.000402	CcSEcCtD
Mesalazine—Nervousness—Doxorubicin—thyroid cancer	7.65e-05	0.0004	CcSEcCtD
Mesalazine—Vertigo—Epirubicin—thyroid cancer	7.65e-05	0.0004	CcSEcCtD
Mesalazine—Syncope—Epirubicin—thyroid cancer	7.64e-05	0.0004	CcSEcCtD
Mesalazine—Leukopenia—Epirubicin—thyroid cancer	7.62e-05	0.000399	CcSEcCtD
Mesalazine—Back pain—Doxorubicin—thyroid cancer	7.62e-05	0.000399	CcSEcCtD
Mesalazine—Muscle spasms—Doxorubicin—thyroid cancer	7.58e-05	0.000396	CcSEcCtD
Mesalazine—Palpitations—Epirubicin—thyroid cancer	7.53e-05	0.000394	CcSEcCtD
Mesalazine—Loss of consciousness—Epirubicin—thyroid cancer	7.48e-05	0.000392	CcSEcCtD
Mesalazine—Cough—Epirubicin—thyroid cancer	7.43e-05	0.000389	CcSEcCtD
Mesalazine—Vision blurred—Doxorubicin—thyroid cancer	7.43e-05	0.000388	CcSEcCtD
Mesalazine—Hypertension—Epirubicin—thyroid cancer	7.35e-05	0.000385	CcSEcCtD
Mesalazine—Ill-defined disorder—Doxorubicin—thyroid cancer	7.31e-05	0.000382	CcSEcCtD
Mesalazine—Anaemia—Doxorubicin—thyroid cancer	7.28e-05	0.000381	CcSEcCtD
Mesalazine—Chest pain—Epirubicin—thyroid cancer	7.25e-05	0.000379	CcSEcCtD
Mesalazine—Arthralgia—Epirubicin—thyroid cancer	7.25e-05	0.000379	CcSEcCtD
Mesalazine—Myalgia—Epirubicin—thyroid cancer	7.25e-05	0.000379	CcSEcCtD
Mesalazine—Anxiety—Epirubicin—thyroid cancer	7.23e-05	0.000378	CcSEcCtD
Mesalazine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—thyroid cancer	7.2e-05	0.000377	CcSEcCtD
Mesalazine—Discomfort—Epirubicin—thyroid cancer	7.16e-05	0.000375	CcSEcCtD
Mesalazine—Malaise—Doxorubicin—thyroid cancer	7.11e-05	0.000372	CcSEcCtD
Mesalazine—Dry mouth—Epirubicin—thyroid cancer	7.09e-05	0.000371	CcSEcCtD
Mesalazine—Vertigo—Doxorubicin—thyroid cancer	7.08e-05	0.00037	CcSEcCtD
Mesalazine—Syncope—Doxorubicin—thyroid cancer	7.07e-05	0.00037	CcSEcCtD
Mesalazine—Leukopenia—Doxorubicin—thyroid cancer	7.05e-05	0.000369	CcSEcCtD
Mesalazine—Confusional state—Epirubicin—thyroid cancer	7.01e-05	0.000367	CcSEcCtD
Mesalazine—Palpitations—Doxorubicin—thyroid cancer	6.96e-05	0.000364	CcSEcCtD
Mesalazine—Anaphylactic shock—Epirubicin—thyroid cancer	6.95e-05	0.000364	CcSEcCtD
Mesalazine—Oedema—Epirubicin—thyroid cancer	6.95e-05	0.000364	CcSEcCtD
Mesalazine—Loss of consciousness—Doxorubicin—thyroid cancer	6.93e-05	0.000362	CcSEcCtD
Mesalazine—Infection—Epirubicin—thyroid cancer	6.9e-05	0.000361	CcSEcCtD
Mesalazine—Cough—Doxorubicin—thyroid cancer	6.88e-05	0.00036	CcSEcCtD
Mesalazine—Shock—Epirubicin—thyroid cancer	6.84e-05	0.000358	CcSEcCtD
Mesalazine—Nervous system disorder—Epirubicin—thyroid cancer	6.82e-05	0.000357	CcSEcCtD
Mesalazine—Thrombocytopenia—Epirubicin—thyroid cancer	6.81e-05	0.000356	CcSEcCtD
Mesalazine—Hypertension—Doxorubicin—thyroid cancer	6.8e-05	0.000356	CcSEcCtD
Mesalazine—Tachycardia—Epirubicin—thyroid cancer	6.78e-05	0.000355	CcSEcCtD
Mesalazine—Skin disorder—Epirubicin—thyroid cancer	6.75e-05	0.000353	CcSEcCtD
Mesalazine—Hyperhidrosis—Epirubicin—thyroid cancer	6.72e-05	0.000351	CcSEcCtD
Mesalazine—Arthralgia—Doxorubicin—thyroid cancer	6.71e-05	0.000351	CcSEcCtD
Mesalazine—Myalgia—Doxorubicin—thyroid cancer	6.71e-05	0.000351	CcSEcCtD
Mesalazine—Chest pain—Doxorubicin—thyroid cancer	6.71e-05	0.000351	CcSEcCtD
Mesalazine—Anxiety—Doxorubicin—thyroid cancer	6.69e-05	0.00035	CcSEcCtD
Mesalazine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—thyroid cancer	6.66e-05	0.000349	CcSEcCtD
Mesalazine—Discomfort—Doxorubicin—thyroid cancer	6.63e-05	0.000347	CcSEcCtD
Mesalazine—Anorexia—Epirubicin—thyroid cancer	6.63e-05	0.000347	CcSEcCtD
Mesalazine—Dry mouth—Doxorubicin—thyroid cancer	6.56e-05	0.000343	CcSEcCtD
Mesalazine—Hypotension—Epirubicin—thyroid cancer	6.49e-05	0.00034	CcSEcCtD
Mesalazine—Confusional state—Doxorubicin—thyroid cancer	6.48e-05	0.000339	CcSEcCtD
Mesalazine—Oedema—Doxorubicin—thyroid cancer	6.43e-05	0.000336	CcSEcCtD
Mesalazine—Anaphylactic shock—Doxorubicin—thyroid cancer	6.43e-05	0.000336	CcSEcCtD
Mesalazine—Infection—Doxorubicin—thyroid cancer	6.39e-05	0.000334	CcSEcCtD
Mesalazine—Musculoskeletal discomfort—Epirubicin—thyroid cancer	6.33e-05	0.000331	CcSEcCtD
Mesalazine—Shock—Doxorubicin—thyroid cancer	6.33e-05	0.000331	CcSEcCtD
Mesalazine—Nervous system disorder—Doxorubicin—thyroid cancer	6.31e-05	0.00033	CcSEcCtD
Mesalazine—Thrombocytopenia—Doxorubicin—thyroid cancer	6.3e-05	0.000329	CcSEcCtD
Mesalazine—Insomnia—Epirubicin—thyroid cancer	6.29e-05	0.000329	CcSEcCtD
Mesalazine—Tachycardia—Doxorubicin—thyroid cancer	6.28e-05	0.000328	CcSEcCtD
Mesalazine—Skin disorder—Doxorubicin—thyroid cancer	6.25e-05	0.000327	CcSEcCtD
Mesalazine—Paraesthesia—Epirubicin—thyroid cancer	6.24e-05	0.000326	CcSEcCtD
Mesalazine—Hyperhidrosis—Doxorubicin—thyroid cancer	6.22e-05	0.000325	CcSEcCtD
Mesalazine—Dyspnoea—Epirubicin—thyroid cancer	6.2e-05	0.000324	CcSEcCtD
Mesalazine—Somnolence—Epirubicin—thyroid cancer	6.18e-05	0.000323	CcSEcCtD
Mesalazine—Anorexia—Doxorubicin—thyroid cancer	6.13e-05	0.000321	CcSEcCtD
Mesalazine—Dyspepsia—Epirubicin—thyroid cancer	6.12e-05	0.00032	CcSEcCtD
Mesalazine—Decreased appetite—Epirubicin—thyroid cancer	6.04e-05	0.000316	CcSEcCtD
Mesalazine—Hypotension—Doxorubicin—thyroid cancer	6.01e-05	0.000314	CcSEcCtD
Mesalazine—Gastrointestinal disorder—Epirubicin—thyroid cancer	6e-05	0.000314	CcSEcCtD
Mesalazine—Fatigue—Epirubicin—thyroid cancer	5.99e-05	0.000313	CcSEcCtD
Mesalazine—Pain—Epirubicin—thyroid cancer	5.94e-05	0.000311	CcSEcCtD
Mesalazine—Constipation—Epirubicin—thyroid cancer	5.94e-05	0.000311	CcSEcCtD
Mesalazine—Musculoskeletal discomfort—Doxorubicin—thyroid cancer	5.86e-05	0.000307	CcSEcCtD
Mesalazine—Insomnia—Doxorubicin—thyroid cancer	5.82e-05	0.000304	CcSEcCtD
Mesalazine—Paraesthesia—Doxorubicin—thyroid cancer	5.77e-05	0.000302	CcSEcCtD
Mesalazine—IKBKB—Toll-like Receptor Signaling Pathway—AKT1—thyroid cancer	5.74e-05	0.000497	CbGpPWpGaD
Mesalazine—Dyspnoea—Doxorubicin—thyroid cancer	5.73e-05	0.0003	CcSEcCtD
Mesalazine—Feeling abnormal—Epirubicin—thyroid cancer	5.73e-05	0.0003	CcSEcCtD
Mesalazine—IKBKB—Fc epsilon receptor (FCERI) signaling—NRAS—thyroid cancer	5.72e-05	0.000496	CbGpPWpGaD
Mesalazine—Somnolence—Doxorubicin—thyroid cancer	5.72e-05	0.000299	CcSEcCtD
Mesalazine—CHUK—Downstream signaling events of B Cell Receptor (BCR)—KRAS—thyroid cancer	5.69e-05	0.000493	CbGpPWpGaD
Mesalazine—Gastrointestinal pain—Epirubicin—thyroid cancer	5.68e-05	0.000297	CcSEcCtD
Mesalazine—Dyspepsia—Doxorubicin—thyroid cancer	5.66e-05	0.000296	CcSEcCtD
Mesalazine—Decreased appetite—Doxorubicin—thyroid cancer	5.59e-05	0.000292	CcSEcCtD
Mesalazine—CHUK—NGF signalling via TRKA from the plasma membrane—NRAS—thyroid cancer	5.59e-05	0.000484	CbGpPWpGaD
Mesalazine—Gastrointestinal disorder—Doxorubicin—thyroid cancer	5.55e-05	0.00029	CcSEcCtD
Mesalazine—Fatigue—Doxorubicin—thyroid cancer	5.54e-05	0.00029	CcSEcCtD
Mesalazine—CHUK—Signaling by SCF-KIT—HRAS—thyroid cancer	5.53e-05	0.00048	CbGpPWpGaD
Mesalazine—Urticaria—Epirubicin—thyroid cancer	5.52e-05	0.000289	CcSEcCtD
Mesalazine—Constipation—Doxorubicin—thyroid cancer	5.5e-05	0.000288	CcSEcCtD
Mesalazine—Pain—Doxorubicin—thyroid cancer	5.5e-05	0.000288	CcSEcCtD
Mesalazine—Abdominal pain—Epirubicin—thyroid cancer	5.49e-05	0.000287	CcSEcCtD
Mesalazine—Body temperature increased—Epirubicin—thyroid cancer	5.49e-05	0.000287	CcSEcCtD
Mesalazine—CHUK—Innate Immune System—NRG1—thyroid cancer	5.48e-05	0.000475	CbGpPWpGaD
Mesalazine—ALOX5—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	5.48e-05	0.000475	CbGpPWpGaD
Mesalazine—CHUK—Integrated Breast Cancer Pathway—TP53—thyroid cancer	5.48e-05	0.000475	CbGpPWpGaD
Mesalazine—CHUK—BDNF signaling pathway—HRAS—thyroid cancer	5.44e-05	0.000472	CbGpPWpGaD
Mesalazine—CHUK—Fc epsilon receptor (FCERI) signaling—KRAS—thyroid cancer	5.43e-05	0.00047	CbGpPWpGaD
Mesalazine—CHUK—DAP12 interactions—KRAS—thyroid cancer	5.43e-05	0.00047	CbGpPWpGaD
Mesalazine—CHUK—Signaling by FGFR in disease—KRAS—thyroid cancer	5.43e-05	0.00047	CbGpPWpGaD
Mesalazine—CHUK—Disease—TPR—thyroid cancer	5.42e-05	0.00047	CbGpPWpGaD
Mesalazine—CHUK—Signaling by EGFR—KRAS—thyroid cancer	5.38e-05	0.000466	CbGpPWpGaD
Mesalazine—CHUK—Disease—PRKAR1A—thyroid cancer	5.33e-05	0.000462	CbGpPWpGaD
Mesalazine—CHUK—Signaling by EGFR in Cancer—KRAS—thyroid cancer	5.33e-05	0.000462	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—TPR—thyroid cancer	5.32e-05	0.000461	CbGpPWpGaD
Mesalazine—CHUK—Signaling by PDGF—KRAS—thyroid cancer	5.31e-05	0.00046	CbGpPWpGaD
Mesalazine—Feeling abnormal—Doxorubicin—thyroid cancer	5.3e-05	0.000277	CcSEcCtD
Mesalazine—CHUK—Downstream signaling of activated FGFR—HRAS—thyroid cancer	5.3e-05	0.000459	CbGpPWpGaD
Mesalazine—IKBKB—B Cell Activation—NRAS—thyroid cancer	5.29e-05	0.000459	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—LGALS3—thyroid cancer	5.28e-05	0.000458	CbGpPWpGaD
Mesalazine—CHUK—Adaptive Immune System—NRG1—thyroid cancer	5.27e-05	0.000456	CbGpPWpGaD
Mesalazine—Gastrointestinal pain—Doxorubicin—thyroid cancer	5.26e-05	0.000275	CcSEcCtD
Mesalazine—IKBKB—Immune System—PRKAR1A—thyroid cancer	5.24e-05	0.000454	CbGpPWpGaD
Mesalazine—CHUK—Signaling by ERBB4—HRAS—thyroid cancer	5.21e-05	0.000452	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—TCF7L1—thyroid cancer	5.19e-05	0.000449	CbGpPWpGaD
Mesalazine—IKBKB—Downstream signaling events of B Cell Receptor (BCR)—KRAS—thyroid cancer	5.16e-05	0.000447	CbGpPWpGaD
Mesalazine—IKBKB—MAPK Signaling Pathway—KRAS—thyroid cancer	5.13e-05	0.000445	CbGpPWpGaD
Mesalazine—Hypersensitivity—Epirubicin—thyroid cancer	5.12e-05	0.000268	CcSEcCtD
Mesalazine—Urticaria—Doxorubicin—thyroid cancer	5.11e-05	0.000267	CcSEcCtD
Mesalazine—CHUK—Integrated Pancreatic Cancer Pathway—KRAS—thyroid cancer	5.11e-05	0.000443	CbGpPWpGaD
Mesalazine—CHUK—Disease—MEN1—thyroid cancer	5.1e-05	0.000442	CbGpPWpGaD
Mesalazine—Body temperature increased—Doxorubicin—thyroid cancer	5.08e-05	0.000266	CcSEcCtD
Mesalazine—Abdominal pain—Doxorubicin—thyroid cancer	5.08e-05	0.000266	CcSEcCtD
Mesalazine—CHUK—B Cell Activation—KRAS—thyroid cancer	5.02e-05	0.000435	CbGpPWpGaD
Mesalazine—Asthenia—Epirubicin—thyroid cancer	4.99e-05	0.000261	CcSEcCtD
Mesalazine—CHUK—Downstream signal transduction—HRAS—thyroid cancer	4.98e-05	0.000431	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—NRG1—thyroid cancer	4.97e-05	0.000431	CbGpPWpGaD
Mesalazine—PTGS2—C-MYB transcription factor network—HRAS—thyroid cancer	4.96e-05	0.00043	CbGpPWpGaD
Mesalazine—CHUK—Signaling by FGFR—HRAS—thyroid cancer	4.95e-05	0.000429	CbGpPWpGaD
Mesalazine—CHUK—Regulation of toll-like receptor signaling pathway—AKT1—thyroid cancer	4.94e-05	0.000428	CbGpPWpGaD
Mesalazine—IKBKB—BDNF signaling pathway—HRAS—thyroid cancer	4.93e-05	0.000428	CbGpPWpGaD
Mesalazine—CHUK—Signaling by ERBB2—HRAS—thyroid cancer	4.93e-05	0.000427	CbGpPWpGaD
Mesalazine—IKBKB—Fc epsilon receptor (FCERI) signaling—KRAS—thyroid cancer	4.92e-05	0.000426	CbGpPWpGaD
Mesalazine—Pruritus—Epirubicin—thyroid cancer	4.92e-05	0.000257	CcSEcCtD
Mesalazine—ALOX5—Metabolism—RXRA—thyroid cancer	4.91e-05	0.000426	CbGpPWpGaD
Mesalazine—CHUK—DAP12 signaling—HRAS—thyroid cancer	4.9e-05	0.000425	CbGpPWpGaD
Mesalazine—CHUK—Signaling by SCF-KIT—AKT1—thyroid cancer	4.89e-05	0.000423	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—TPR—thyroid cancer	4.84e-05	0.000419	CbGpPWpGaD
Mesalazine—CHUK—Downstream signaling events of B Cell Receptor (BCR)—HRAS—thyroid cancer	4.83e-05	0.000419	CbGpPWpGaD
Mesalazine—CHUK—Signaling by NGF—PTEN—thyroid cancer	4.82e-05	0.000417	CbGpPWpGaD
Mesalazine—CHUK—NGF signalling via TRKA from the plasma membrane—KRAS—thyroid cancer	4.81e-05	0.000417	CbGpPWpGaD
Mesalazine—CHUK—BDNF signaling pathway—AKT1—thyroid cancer	4.81e-05	0.000416	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	4.78e-05	0.000415	CbGpPWpGaD
Mesalazine—ALOX5—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	4.78e-05	0.000414	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—NRG1—thyroid cancer	4.77e-05	0.000414	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—PRKAR1A—thyroid cancer	4.76e-05	0.000412	CbGpPWpGaD
Mesalazine—Diarrhoea—Epirubicin—thyroid cancer	4.76e-05	0.000249	CcSEcCtD
Mesalazine—Hypersensitivity—Doxorubicin—thyroid cancer	4.74e-05	0.000248	CcSEcCtD
Mesalazine—IKBKB—Signaling Pathways—TCF7L1—thyroid cancer	4.7e-05	0.000408	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—HPGD—thyroid cancer	4.68e-05	0.000406	CbGpPWpGaD
Mesalazine—CHUK—Downstream signaling of activated FGFR—AKT1—thyroid cancer	4.68e-05	0.000405	CbGpPWpGaD
Mesalazine—PPARG—Circadian rythm related genes—TP53—thyroid cancer	4.64e-05	0.000402	CbGpPWpGaD
Mesalazine—CHUK—Integrated Breast Cancer Pathway—AKT1—thyroid cancer	4.63e-05	0.000401	CbGpPWpGaD
Mesalazine—Asthenia—Doxorubicin—thyroid cancer	4.61e-05	0.000241	CcSEcCtD
Mesalazine—CHUK—Fc epsilon receptor (FCERI) signaling—HRAS—thyroid cancer	4.61e-05	0.0004	CbGpPWpGaD
Mesalazine—CHUK—Signaling by FGFR in disease—HRAS—thyroid cancer	4.61e-05	0.0004	CbGpPWpGaD
Mesalazine—CHUK—DAP12 interactions—HRAS—thyroid cancer	4.61e-05	0.0004	CbGpPWpGaD
Mesalazine—CHUK—Signaling by ERBB4—AKT1—thyroid cancer	4.6e-05	0.000399	CbGpPWpGaD
Mesalazine—Dizziness—Epirubicin—thyroid cancer	4.6e-05	0.00024	CcSEcCtD
Mesalazine—CHUK—Signaling by EGFR—HRAS—thyroid cancer	4.57e-05	0.000396	CbGpPWpGaD
Mesalazine—IKBKB—MAPK Signaling Pathway—TP53—thyroid cancer	4.56e-05	0.000395	CbGpPWpGaD
Mesalazine—IKBKB—B Cell Activation—KRAS—thyroid cancer	4.56e-05	0.000395	CbGpPWpGaD
Mesalazine—Pruritus—Doxorubicin—thyroid cancer	4.55e-05	0.000238	CcSEcCtD
Mesalazine—CHUK—Integrated Pancreatic Cancer Pathway—TP53—thyroid cancer	4.54e-05	0.000393	CbGpPWpGaD
Mesalazine—IKBKB—Insulin Signaling—HRAS—thyroid cancer	4.54e-05	0.000393	CbGpPWpGaD
Mesalazine—CHUK—Signaling by EGFR in Cancer—HRAS—thyroid cancer	4.53e-05	0.000393	CbGpPWpGaD
Mesalazine—CHUK—Signaling by PDGF—HRAS—thyroid cancer	4.51e-05	0.000391	CbGpPWpGaD
Mesalazine—IKBKB—Regulation of toll-like receptor signaling pathway—AKT1—thyroid cancer	4.48e-05	0.000388	CbGpPWpGaD
Mesalazine—Vomiting—Epirubicin—thyroid cancer	4.42e-05	0.000231	CcSEcCtD
Mesalazine—Diarrhoea—Doxorubicin—thyroid cancer	4.4e-05	0.00023	CcSEcCtD
Mesalazine—CHUK—Downstream signal transduction—AKT1—thyroid cancer	4.39e-05	0.000381	CbGpPWpGaD
Mesalazine—PTGS2—Disease—TCF7L1—thyroid cancer	4.39e-05	0.00038	CbGpPWpGaD
Mesalazine—IKBKB—Downstream signaling events of B Cell Receptor (BCR)—HRAS—thyroid cancer	4.38e-05	0.00038	CbGpPWpGaD
Mesalazine—Rash—Epirubicin—thyroid cancer	4.38e-05	0.000229	CcSEcCtD
Mesalazine—Dermatitis—Epirubicin—thyroid cancer	4.38e-05	0.000229	CcSEcCtD
Mesalazine—CHUK—Signaling by FGFR—AKT1—thyroid cancer	4.37e-05	0.000379	CbGpPWpGaD
Mesalazine—CHUK—Cytokine Signaling in Immune system—NRAS—thyroid cancer	4.37e-05	0.000379	CbGpPWpGaD
Mesalazine—IKBKB—Signaling by NGF—PTEN—thyroid cancer	4.37e-05	0.000378	CbGpPWpGaD
Mesalazine—IKBKB—BDNF signaling pathway—AKT1—thyroid cancer	4.36e-05	0.000378	CbGpPWpGaD
Mesalazine—Headache—Epirubicin—thyroid cancer	4.35e-05	0.000228	CcSEcCtD
Mesalazine—CHUK—Signaling by ERBB2—AKT1—thyroid cancer	4.35e-05	0.000377	CbGpPWpGaD
Mesalazine—CHUK—DAP12 signaling—AKT1—thyroid cancer	4.33e-05	0.000375	CbGpPWpGaD
Mesalazine—CHUK—Signaling by NGF—NRAS—thyroid cancer	4.3e-05	0.000372	CbGpPWpGaD
Mesalazine—CHUK—B Cell Activation—HRAS—thyroid cancer	4.27e-05	0.00037	CbGpPWpGaD
Mesalazine—CHUK—Downstream signaling events of B Cell Receptor (BCR)—AKT1—thyroid cancer	4.27e-05	0.00037	CbGpPWpGaD
Mesalazine—Dizziness—Doxorubicin—thyroid cancer	4.25e-05	0.000222	CcSEcCtD
Mesalazine—IKBKB—Fc epsilon receptor (FCERI) signaling—HRAS—thyroid cancer	4.18e-05	0.000363	CbGpPWpGaD
Mesalazine—Nausea—Epirubicin—thyroid cancer	4.13e-05	0.000216	CcSEcCtD
Mesalazine—Vomiting—Doxorubicin—thyroid cancer	4.09e-05	0.000214	CcSEcCtD
Mesalazine—CHUK—NGF signalling via TRKA from the plasma membrane—HRAS—thyroid cancer	4.09e-05	0.000354	CbGpPWpGaD
Mesalazine—PTGS2—Integrated Pancreatic Cancer Pathway—CCND1—thyroid cancer	4.08e-05	0.000354	CbGpPWpGaD
Mesalazine—CHUK—DAP12 interactions—AKT1—thyroid cancer	4.07e-05	0.000353	CbGpPWpGaD
Mesalazine—CHUK—Fc epsilon receptor (FCERI) signaling—AKT1—thyroid cancer	4.07e-05	0.000353	CbGpPWpGaD
Mesalazine—CHUK—Signaling by FGFR in disease—AKT1—thyroid cancer	4.07e-05	0.000353	CbGpPWpGaD
Mesalazine—CHUK—Disease—CALCA—thyroid cancer	4.06e-05	0.000352	CbGpPWpGaD
Mesalazine—Rash—Doxorubicin—thyroid cancer	4.05e-05	0.000212	CcSEcCtD
Mesalazine—Dermatitis—Doxorubicin—thyroid cancer	4.05e-05	0.000212	CcSEcCtD
Mesalazine—CHUK—Signaling by EGFR—AKT1—thyroid cancer	4.04e-05	0.00035	CbGpPWpGaD
Mesalazine—Headache—Doxorubicin—thyroid cancer	4.03e-05	0.000211	CcSEcCtD
Mesalazine—IKBKB—Insulin Signaling—AKT1—thyroid cancer	4e-05	0.000347	CbGpPWpGaD
Mesalazine—CHUK—Signaling by EGFR in Cancer—AKT1—thyroid cancer	4e-05	0.000347	CbGpPWpGaD
Mesalazine—CHUK—Signaling by PDGF—AKT1—thyroid cancer	3.98e-05	0.000345	CbGpPWpGaD
Mesalazine—CHUK—Immune System—CDK1—thyroid cancer	3.98e-05	0.000345	CbGpPWpGaD
Mesalazine—IKBKB—Cytokine Signaling in Immune system—NRAS—thyroid cancer	3.96e-05	0.000343	CbGpPWpGaD
Mesalazine—PTGS2—Spinal Cord Injury—TP53—thyroid cancer	3.95e-05	0.000342	CbGpPWpGaD
Mesalazine—PTGS2—Integrated Pancreatic Cancer Pathway—PTEN—thyroid cancer	3.94e-05	0.000341	CbGpPWpGaD
Mesalazine—PPARG—Gene Expression—RXRA—thyroid cancer	3.91e-05	0.000339	CbGpPWpGaD
Mesalazine—IKBKB—Signaling by NGF—NRAS—thyroid cancer	3.9e-05	0.000338	CbGpPWpGaD
Mesalazine—IKBKB—B Cell Activation—HRAS—thyroid cancer	3.87e-05	0.000335	CbGpPWpGaD
Mesalazine—IKBKB—Downstream signaling events of B Cell Receptor (BCR)—AKT1—thyroid cancer	3.87e-05	0.000335	CbGpPWpGaD
Mesalazine—IKBKB—MAPK Signaling Pathway—AKT1—thyroid cancer	3.85e-05	0.000334	CbGpPWpGaD
Mesalazine—CHUK—Integrated Pancreatic Cancer Pathway—AKT1—thyroid cancer	3.83e-05	0.000332	CbGpPWpGaD
Mesalazine—CHUK—Immune System—IFNA2—thyroid cancer	3.83e-05	0.000332	CbGpPWpGaD
Mesalazine—Nausea—Doxorubicin—thyroid cancer	3.82e-05	0.0002	CcSEcCtD
Mesalazine—PTGS2—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	3.8e-05	0.000329	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—TSHR—thyroid cancer	3.8e-05	0.000329	CbGpPWpGaD
Mesalazine—CHUK—B Cell Activation—AKT1—thyroid cancer	3.77e-05	0.000327	CbGpPWpGaD
Mesalazine—CHUK—Cytokine Signaling in Immune system—KRAS—thyroid cancer	3.76e-05	0.000326	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—PRKAR1A—thyroid cancer	3.73e-05	0.000324	CbGpPWpGaD
Mesalazine—CHUK—Signaling by NGF—KRAS—thyroid cancer	3.7e-05	0.00032	CbGpPWpGaD
Mesalazine—IKBKB—Fc epsilon receptor (FCERI) signaling—AKT1—thyroid cancer	3.69e-05	0.00032	CbGpPWpGaD
Mesalazine—CHUK—Disease—CDK1—thyroid cancer	3.67e-05	0.000318	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—SLC5A5—thyroid cancer	3.62e-05	0.000314	CbGpPWpGaD
Mesalazine—CHUK—NGF signalling via TRKA from the plasma membrane—AKT1—thyroid cancer	3.61e-05	0.000313	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—CDK1—thyroid cancer	3.61e-05	0.000313	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—MEN1—thyroid cancer	3.57e-05	0.000309	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—IFNA2—thyroid cancer	3.47e-05	0.000301	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—TSHR—thyroid cancer	3.44e-05	0.000298	CbGpPWpGaD
Mesalazine—IKBKB—B Cell Activation—AKT1—thyroid cancer	3.42e-05	0.000296	CbGpPWpGaD
Mesalazine—IKBKB—Cytokine Signaling in Immune system—KRAS—thyroid cancer	3.41e-05	0.000295	CbGpPWpGaD
Mesalazine—PPARG—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	3.39e-05	0.000294	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—TPR—thyroid cancer	3.39e-05	0.000294	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—PRKAR1A—thyroid cancer	3.39e-05	0.000293	CbGpPWpGaD
Mesalazine—IKBKB—Signaling by NGF—KRAS—thyroid cancer	3.35e-05	0.000291	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—PRKAR1A—thyroid cancer	3.33e-05	0.000289	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—MEN1—thyroid cancer	3.24e-05	0.00028	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—PTCH1—thyroid cancer	3.23e-05	0.00028	CbGpPWpGaD
Mesalazine—PTGS2—Disease—TPR—thyroid cancer	3.21e-05	0.000278	CbGpPWpGaD
Mesalazine—CHUK—Cytokine Signaling in Immune system—HRAS—thyroid cancer	3.2e-05	0.000277	CbGpPWpGaD
Mesalazine—CHUK—Immune System—NRG1—thyroid cancer	3.19e-05	0.000277	CbGpPWpGaD
Mesalazine—PTGS2—Disease—PRKAR1A—thyroid cancer	3.16e-05	0.000274	CbGpPWpGaD
Mesalazine—CHUK—Signaling by NGF—HRAS—thyroid cancer	3.14e-05	0.000272	CbGpPWpGaD
Mesalazine—ALOX5—Metabolism—PPARG—thyroid cancer	3.1e-05	0.000269	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—RXRA—thyroid cancer	3.04e-05	0.000264	CbGpPWpGaD
Mesalazine—PTGS2—Integrated Pancreatic Cancer Pathway—KRAS—thyroid cancer	3.03e-05	0.000262	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	3.02e-05	0.000262	CbGpPWpGaD
Mesalazine—PTGS2—Disease—MEN1—thyroid cancer	3.02e-05	0.000262	CbGpPWpGaD
Mesalazine—PPARG—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	2.96e-05	0.000256	CbGpPWpGaD
Mesalazine—PPARG—Developmental Biology—NRAS—thyroid cancer	2.96e-05	0.000256	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—SST—thyroid cancer	2.95e-05	0.000256	CbGpPWpGaD
Mesalazine—CHUK—Disease—NRG1—thyroid cancer	2.95e-05	0.000256	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—PTCH1—thyroid cancer	2.93e-05	0.000254	CbGpPWpGaD
Mesalazine—IKBKB—Cytokine Signaling in Immune system—HRAS—thyroid cancer	2.9e-05	0.000251	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—NRG1—thyroid cancer	2.9e-05	0.000251	CbGpPWpGaD
Mesalazine—IKBKB—Signaling by NGF—HRAS—thyroid cancer	2.85e-05	0.000247	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—CALCA—thyroid cancer	2.84e-05	0.000246	CbGpPWpGaD
Mesalazine—CHUK—Signaling by NGF—AKT1—thyroid cancer	2.78e-05	0.00024	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—PTEN—thyroid cancer	2.75e-05	0.000238	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—TPR—thyroid cancer	2.69e-05	0.000233	CbGpPWpGaD
Mesalazine—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—thyroid cancer	2.69e-05	0.000233	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—SST—thyroid cancer	2.68e-05	0.000232	CbGpPWpGaD
Mesalazine—CHUK—Disease—TERT—thyroid cancer	2.65e-05	0.000229	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—PRKAR1A—thyroid cancer	2.65e-05	0.000229	CbGpPWpGaD
Mesalazine—CHUK—Adaptive Immune System—PTEN—thyroid cancer	2.64e-05	0.000229	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—CALCA—thyroid cancer	2.58e-05	0.000223	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—CDK1—thyroid cancer	2.57e-05	0.000223	CbGpPWpGaD
Mesalazine—PPARG—Developmental Biology—KRAS—thyroid cancer	2.54e-05	0.00022	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—SLC5A5—thyroid cancer	2.54e-05	0.00022	CbGpPWpGaD
Mesalazine—CHUK—Disease—HIF1A—thyroid cancer	2.53e-05	0.000219	CbGpPWpGaD
Mesalazine—IKBKB—Signaling by NGF—AKT1—thyroid cancer	2.52e-05	0.000218	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—PTEN—thyroid cancer	2.49e-05	0.000216	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—NRAS—thyroid cancer	2.45e-05	0.000212	CbGpPWpGaD
Mesalazine—ALOX5—Metabolism—PTGS2—thyroid cancer	2.44e-05	0.000211	CbGpPWpGaD
Mesalazine—PTGS2—Disease—CALCA—thyroid cancer	2.4e-05	0.000208	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	2.4e-05	0.000208	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—PTEN—thyroid cancer	2.39e-05	0.000207	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	2.38e-05	0.000206	CbGpPWpGaD
Mesalazine—CHUK—Adaptive Immune System—NRAS—thyroid cancer	2.35e-05	0.000204	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—CDK1—thyroid cancer	2.33e-05	0.000202	CbGpPWpGaD
Mesalazine—PTGS2—Integrated Pancreatic Cancer Pathway—AKT1—thyroid cancer	2.27e-05	0.000197	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—NRAS—thyroid cancer	2.22e-05	0.000193	CbGpPWpGaD
Mesalazine—PTGS2—Disease—CDK1—thyroid cancer	2.18e-05	0.000189	CbGpPWpGaD
Mesalazine—PPARG—Developmental Biology—HRAS—thyroid cancer	2.16e-05	0.000187	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—NRAS—thyroid cancer	2.13e-05	0.000185	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—RXRA—thyroid cancer	2.13e-05	0.000185	CbGpPWpGaD
Mesalazine—ALOX5—Metabolism—PTEN—thyroid cancer	2.13e-05	0.000184	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—KRAS—thyroid cancer	2.11e-05	0.000183	CbGpPWpGaD
Mesalazine—CHUK—Disease—BRAF—thyroid cancer	2.1e-05	0.000182	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	2.07e-05	0.00018	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—NRG1—thyroid cancer	2.06e-05	0.000179	CbGpPWpGaD
Mesalazine—CHUK—Adaptive Immune System—KRAS—thyroid cancer	2.03e-05	0.000175	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—SLC5A5—thyroid cancer	2.01e-05	0.000174	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—KRAS—thyroid cancer	1.91e-05	0.000166	CbGpPWpGaD
Mesalazine—PPARG—Developmental Biology—AKT1—thyroid cancer	1.91e-05	0.000165	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—NRG1—thyroid cancer	1.87e-05	0.000162	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—TERT—thyroid cancer	1.85e-05	0.000161	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—KRAS—thyroid cancer	1.84e-05	0.000159	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—HRAS—thyroid cancer	1.79e-05	0.000155	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—HIF1A—thyroid cancer	1.77e-05	0.000154	CbGpPWpGaD
Mesalazine—PTGS2—Disease—NRG1—thyroid cancer	1.75e-05	0.000151	CbGpPWpGaD
Mesalazine—CHUK—Adaptive Immune System—HRAS—thyroid cancer	1.72e-05	0.000149	CbGpPWpGaD
Mesalazine—CHUK—Disease—PTGS2—thyroid cancer	1.69e-05	0.000147	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—RXRA—thyroid cancer	1.69e-05	0.000147	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—TERT—thyroid cancer	1.68e-05	0.000146	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	1.65e-05	0.000143	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—HRAS—thyroid cancer	1.63e-05	0.000141	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—HIF1A—thyroid cancer	1.61e-05	0.000139	CbGpPWpGaD
Mesalazine—CHUK—Immune System—PTEN—thyroid cancer	1.6e-05	0.000139	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—AKT1—thyroid cancer	1.58e-05	0.000137	CbGpPWpGaD
Mesalazine—PTGS2—Disease—TERT—thyroid cancer	1.57e-05	0.000136	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—HRAS—thyroid cancer	1.56e-05	0.000135	CbGpPWpGaD
Mesalazine—CHUK—Adaptive Immune System—AKT1—thyroid cancer	1.52e-05	0.000132	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—PTGS2—thyroid cancer	1.51e-05	0.000131	CbGpPWpGaD
Mesalazine—PTGS2—Disease—HIF1A—thyroid cancer	1.5e-05	0.00013	CbGpPWpGaD
Mesalazine—CHUK—Disease—PTEN—thyroid cancer	1.48e-05	0.000128	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—BRAF—thyroid cancer	1.47e-05	0.000127	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—PTEN—thyroid cancer	1.45e-05	0.000126	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—AKT1—thyroid cancer	1.44e-05	0.000124	CbGpPWpGaD
Mesalazine—CHUK—Immune System—NRAS—thyroid cancer	1.43e-05	0.000124	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—AKT1—thyroid cancer	1.38e-05	0.000119	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—PPARG—thyroid cancer	1.35e-05	0.000117	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—BRAF—thyroid cancer	1.33e-05	0.000115	CbGpPWpGaD
Mesalazine—CHUK—Disease—NRAS—thyroid cancer	1.32e-05	0.000114	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—PTEN—thyroid cancer	1.32e-05	0.000114	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—NRAS—thyroid cancer	1.29e-05	0.000112	CbGpPWpGaD
Mesalazine—PTGS2—Disease—BRAF—thyroid cancer	1.24e-05	0.000108	CbGpPWpGaD
Mesalazine—CHUK—Immune System—KRAS—thyroid cancer	1.23e-05	0.000106	CbGpPWpGaD
Mesalazine—ALOX5—Metabolism—AKT1—thyroid cancer	1.23e-05	0.000106	CbGpPWpGaD
Mesalazine—CHUK—Disease—KRAS—thyroid cancer	1.13e-05	9.83e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—KRAS—thyroid cancer	1.11e-05	9.65e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—CCND1—thyroid cancer	1.07e-05	9.28e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—PPARG—thyroid cancer	1.07e-05	9.25e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—PTGS2—thyroid cancer	1.06e-05	9.17e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—HRAS—thyroid cancer	1.04e-05	9.05e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—PTEN—thyroid cancer	1.03e-05	8.96e-05	CbGpPWpGaD
Mesalazine—PPARG—Gene Expression—AKT1—thyroid cancer	9.77e-06	8.46e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—CCND1—thyroid cancer	9.72e-06	8.42e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—HRAS—thyroid cancer	9.64e-06	8.35e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—HRAS—thyroid cancer	9.47e-06	8.2e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—PTEN—thyroid cancer	9.38e-06	8.13e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—PTEN—thyroid cancer	9.23e-06	8e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—NRAS—thyroid cancer	9.23e-06	8e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—AKT1—thyroid cancer	9.22e-06	7.99e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—PTEN—thyroid cancer	8.75e-06	7.58e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—AKT1—thyroid cancer	8.51e-06	7.38e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—NRAS—thyroid cancer	8.37e-06	7.25e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—AKT1—thyroid cancer	8.36e-06	7.24e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—KRAS—thyroid cancer	7.94e-06	6.88e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—NRAS—thyroid cancer	7.81e-06	6.76e-05	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—AKT1—thyroid cancer	7.59e-06	6.58e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—PTEN—thyroid cancer	7.33e-06	6.35e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—KRAS—thyroid cancer	7.2e-06	6.24e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—TP53—thyroid cancer	7.06e-06	6.12e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—HRAS—thyroid cancer	6.75e-06	5.85e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—KRAS—thyroid cancer	6.72e-06	5.82e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—TP53—thyroid cancer	6.4e-06	5.55e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—HRAS—thyroid cancer	6.12e-06	5.3e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—AKT1—thyroid cancer	5.96e-06	5.16e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—HRAS—thyroid cancer	5.71e-06	4.95e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—AKT1—thyroid cancer	5.4e-06	4.68e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—AKT1—thyroid cancer	5.32e-06	4.61e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—AKT1—thyroid cancer	5.04e-06	4.37e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—AKT1—thyroid cancer	4.22e-06	3.66e-05	CbGpPWpGaD
